(Press-News.org) An investigational malaria vaccine has been found to be safe, to generate an immune system response, and to offer protection against malaria infection in healthy adults, according to the results of an early-stage clinical trial published Aug. 8 in the journal Science.
The vaccine, known as PfSPZ Vaccine, was developed by scientists at Sanaria Inc., of Rockville, Md. The clinical evaluation was conducted by researchers at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and their collaborators at the Walter Reed Army Institute of Research and the Naval Medical Research Center, both in Silver Spring, Md.
Malaria is transmitted to humans by the bite of an infected mosquito. After the bite occurs, infectious malaria parasites in the immature, sporozoite stage of their life cycle first travel to the liver, where they multiply, and then spread through the bloodstream, at which time symptoms develop.
The PfSPZ Vaccine is composed of live but weakened sporozoites of the species Plasmodium falciparum, the most deadly of the malaria-causing parasites.
"The global burden of malaria is extraordinary and unacceptable," said NIAID Director Anthony S. Fauci, M.D. "Scientists and health care providers have made significant gains in characterizing, treating and preventing malaria; however, a vaccine has remained an elusive goal. We are encouraged by this important step forward."
The Phase I trial, which took place at the NIH Clinical Center in Bethesda, received informed consent from and enrolled 57 healthy adult volunteers ages 18 to 45 years who never had malaria. Of these, 40 participants received the vaccine and 17 did not. To evaluate the vaccine's safety, vaccinees were split into groups receiving two to six intravenous doses of PfSPZ Vaccine at increasing dosages. After vaccination, participants were monitored closely for seven days. No severe adverse effects associated with the vaccine occurred, and no malaria infections related to vaccination were observed.
Based on blood measurements, researchers found that participants who received a higher total dosage of PfSPZ Vaccine generated more antibodies against malaria and more T cells—a type of immune system cell—specific to the vaccine.
To evaluate whether and how well the PfSPZ Vaccine prevented malaria infection, each participant—the vaccinees as well as the control group that did not receive vaccine—was exposed to bites by five mosquitoes carrying the P. falciparum strain from which the PfSPZ Vaccine was derived. This controlled human malaria infection procedure—a standard process in malaria vaccine trials—took place three weeks after participants received their final vaccination. Participants were monitored as outpatients for seven days and then admitted to the NIH Clinical Center, where they stayed until they were diagnosed with malaria, treated with anti-malarial drugs and cured of infection, or shown to be free of infection.
The researchers found that the higher dosages of PfSPZ Vaccine were associated with protection against malaria infection. Only three of the 15 participants who received higher dosages of the vaccine became infected, compared to 16 of 17 participants in the lower dosage group who became infected. Among the 12 participants who received no vaccine, 11 participants became infected after mosquito challenge.
"In this trial, we showed in principle that sporozoites can be developed into a malaria vaccine that confers high levels of protection and is made using the good manufacturing practices that are required for vaccine licensure ," said Robert A. Seder, M.D., chief of the Cellular Immunology Section of the NIAID Vaccine Research Center and principal investigator of the trial.
An important challenge in the continued development of PfSPZ Vaccine is that the vaccine currently is administered intravenously—a rare delivery route for vaccines. Previous studies at lower doses have shown that the more common intradermal (into the skin) and subcutaneous (under the skin) routes did not yield as strong an immune response as the intravenous route.
"Despite this challenge, these trial results are a promising first step in generating high-level protection against malaria, and they allow for future studies to optimize the dose, schedule and delivery route of the candidate vaccine," said Dr. Seder.
A number of follow-up studies are planned, including research to evaluate the vaccine's different dose schedules, possible protection against other Plasmodium strains and the durability of protection. The researchers may also evaluate whether higher doses administered subcutaneously or intradermally provide the same level of protection as that found in this study.
###
NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.niaid.nih.gov.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.
NIH...Turning Discovery Into Health®
References:
Seder et al. Protection against malaria by intravenous immunization with a non-replicating sporozoite vaccine. Science Express. DOI: 10.1126/science.1241800 (2013).
NIH Clinical Center. Clinical trial: Experimental PfSPZ vaccine in adults without malaria (http://clinicaltrials.gov/ct2/show/NCT01441167). ClinicalTrials.gov Identifier: NCT01441167.
For more information, see the NIAID Media Availabilities on the results of an earlier trial of PfSPZ (http://www.niaid.nih.gov/news/newsreleases/2011/Pages/MalariaCD8Vax.aspx)and the launch of the study described in this release (http://www.niaid.nih.gov/news/newsreleases/2012/Pages/MalariaVRC312.aspx).
END
Periodic flooding in Texas—one the most flood-prone states in the nation—cannot be firmly linked to climate change due to numerous dams and other manmade structures introduced over the years, according to a University of Iowa study.
The researchers also found that tropical cyclones are less responsible for major floods in the region than in the eastern United States.
The study, which looked at 70 years of records, appears in the August 2013 issue of the Journal of the American Water Resources Association.
Lead author Gabriele Villarini, assistant professor in the ...
LA JOLLA, CA—August 8, 2012—A small group of immune-regulating molecules, when overproduced even moderately, can trigger the blood cancers known as lymphomas, according to a new study led by scientists from The Scripps Research Institute (TSRI).
The six "microRNA" molecules were already known to be overproduced in lymphomas and in many other human cancers, but no one had demonstrated that they can be the prime cause of such cancers—until now. The new study also identified the major biological pathways through which these microRNAs ignite and maintain cancerous growth.
"We ...
Ten years ago, scientists announced the end of the Human Genome Project, the international attempt to learn which combination of four nucleotides—adenine, thymine, cytosine, and guanine—is unique to homo sapien DNA. This biological alphabet helped researchers identify the approximately 25,000 genes coded in the human genome, but as time went on, questions arose about how all of these genes are controlled.
Now, Harvard Stem Cell Institute Principal Faculty member Alexander Meissner, PhD, reports another milestone, this time contributing to the multilayered NIH-funded human ...
Scientists would like to apply the same principles by which baking soda removes food odors from refrigerators or silica powder keeps moisture away from electronic devices to scrub carbon dioxide from the exhaust gases of fossil fuel power plants. An excellent candidate for this task is the class of materials known as multivariate metal organic frameworks or MTV-MOFs, which were discovered by Omar Yaghi, one of the world's most cited chemists. However, finding and synthesizing the best MTV-MOFs for this task has been a major challenge. That discouraging state-of-affairs ...
Astronomers using NASA's Hubble Space Telescope have solved a 40-year mystery on the origin of the Magellanic Stream, a long ribbon of gas stretching nearly halfway around our Milky Way galaxy.
The Large and Small Magellanic Clouds, two dwarf galaxies orbiting the Milky Way, are at the head of the gaseous stream. Since the stream's discovery by radio telescopes in the early 1970s, astronomers have wondered whether the gas comes from one or both of the satellite galaxies. New Hubble observations reveal most of the gas was stripped from the Small Magellanic Cloud about ...
NOAA scientists report the discovery of the first known colony of table coral off of the south shore of O'ahu in Hawai'i. A report on the discovery was published last month in the Bulletin of Marine Science.
Given its common name due to its flat-topped, table-like shape, table coral (Acropora cytherea) is one of the primary reef-building corals throughout most of the tropical Pacific, but it has never been observed in waters off O'ahu - until now, researchers said. The coral, estimated to be 14 years old, was found at a depth of 60 feet during a training dive.
"This ...
Generally, FDA-approved clinical trials progress through three phases: the first shows safety, the second starts to explore effects and the third seeks to prove a drug's superiority over existing treatments. But when a drug's benefit is obvious in the first or second phase, is the third, costly phase needed? The question is posed in a recent edition of the journal Nature Reviews: Clinical Oncology by Robert C. Doebele, MD, PhD, investigator at the University of Colorado Cancer Center and assistant professor of medical oncology at the CU School of Medicine.
Doebele points ...
Gemini Observatory's latest instrument, a powerful infrared camera and spectrograph at Gemini South, reveals its potential in a series of striking on-sky commissioning images released today.
Gemini Observatory's latest tool for astronomers, a second-generation infrared instrument called FLAMINGOS-2, has "traveled a long road" to begin science observations for the Gemini scientific community. Recent images taken by FLAMINGOS-2 during its last commissioning phase dramatically illustrate that the instrument was worth the wait for astronomers around the world who are anxious ...
A faith-based prisoner re-entry program in Minnesota has saved an estimated $3 million by reducing recidivism, according to a Baylor University study published in the International Journal of Criminology and Sociology.
The study is a cost-benefit analysis of the InnerChange Freedom Initiative, a program which relies heavily on volunteers and is privately funded, said study co-author Byron Johnson, Ph.D., co-director of Baylor's Institute for Studies of Religion (ISR).
"The InnerChange program is a boon to taxpayers. It doesn't rely on public funding. Yet, at the same ...
Researchers at the Moffitt Cancer Center have identified four inherited genetic variants in non-small cell lung cancer patients that can help predict survival and treatment response. Their findings could help lead to more personalized treatment options and improved outcomes for patients.
The researchers analyzed DNA sequence variations in 651 non-small cell lung cancer patients, paying close attention to 53 inflammation-related genes. They found that four of the top 15 variants associated with survival were located on one specific gene (TNFRSF10B). In the study, these ...
